Abbott develops a new generation of drug-eluting stents into clinical trials

Release date: 2009-05-04


Recently, Abbott has developed a new generation of drug-eluting stent technology - XIENCE V everolimus drug-eluting stent, which brings new hope for the treatment of coronary heart disease.

According to reports, XIENCE V is based on Abbott's MULTI-LINK VISION coronary bare metal stent system. In 2006, XIENCE V was approved for listing in Europe and other international markets. In July 2008, the US Food and Drug Administration approved the technology to be listed in the United States. In China, XIENCE V is currently being approved by the State Food and Drug Administration (SFDA) as a medical device for clinical trials.

According to clinical data published at the 2009 China Interventional Cardiology Congress (CIT) in Beijing, patients with coronary heart disease receive a new generation of everolimus-eluting stents compared with the first-generation paclitaxel-eluting stent. Years can reduce the risk of major cardiovascular adverse events. At the seminar, Abbott published independent meta-analysis data from two randomized clinical trials (SPIRIT II trial and SPIRIT III trial): a meta-analysis of 1,302 patients from Europe and Asia showed that compared to the first-generation paclitaxel drug With the eluting stent TAXUS, Abbott’s new generation of XIENCE V everolimus-eluting stents can significantly reduce major cardiovascular adverse events (MACE) by 45%, including cardiac death, myocardial infarction, and target lesion revascularization.

Coronary heart disease is one of the most common types of heart disease. It refers to myocardial dysfunction and/or organic disease caused by coronary artery stenosis and insufficient blood supply. It is also called ischemic cardiomyopathy. Professor Ge Junbo from Shanghai Zhongshan Hospital believes that the incidence of coronary heart disease has gradually increased in recent years, and it is showing a trend of rejuvenation. The results of the SPIRIT II and SPIRIT III clinical trials have brought us new hopes. I believe that after XIENCE V comes to China, the majority of Chinese patients with coronary heart disease will benefit from the XIENCE V drug-eluting stent. ——Shanghai Medical Device Industry Association

Health care or healthcare is the maintenance or improvement of health via the prevention, diagnosis, and treatment of disease, illness, injury, and other physical and mental impairments in human beings. Healthcare is delivered by health professionals (providers or practitioners) in allied health fields. Physicians and physician associates are a part of these health professionals. Dentistry, midwifery, nursing, medicine, optometry, audiology, pharmacy, psychology, occupational therapy, physical therapy and other health professions are all part of healthcare. It includes work done in providing primary care, secondary care, and tertiary care, as well as in public health.

goji instant powder

Health Care Products

Dried Red Goji Berries,Lycium Barbarum Shrub,Purple Dry Berries,Superfood Goji Berries

Jiangxi Institute of Biological Products Inc. , https://www.jxinstitute.com